Mirum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MIRM) $31.70 -0.30 (-0.94%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$30.97▼$32.3150-Day Range$27.14▼$32.3552-Week Range$17.49▼$33.39Volume644,779 shsAverage Volume496,077 shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$54.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Mirum Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside72.8% Upside$54.78 Price TargetShort InterestBearish13.64% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.62Based on 2 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthGrowingFrom ($2.45) to ($0.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector301st out of 952 stocksPharmaceutical Preparations Industry128th out of 434 stocks 4.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.78, Mirum Pharmaceuticals has a forecasted upside of 72.8% from its current price of $31.70.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.64% of the outstanding shares of Mirum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently increased by 4.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 1.5 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Mirum Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $438,516.00 in company stock and sold $454,912.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($2.45) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -7.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 8.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesDecember 4, 2023 | benzinga.comMirum Pharmaceuticals Stock (NASDAQ:MIRM) Insider TradesNovember 28, 2023 | americanbankingnews.comMirum Pharmaceuticals' (MIRM) "Overweight" Rating Reaffirmed at Cantor FitzgeraldDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 22, 2023 | morningstar.comMirum Pharmaceuticals Inc MIRMNovember 20, 2023 | finance.yahoo.comMirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx ConferenceNovember 20, 2023 | markets.businessinsider.com11 Analysts Have This to Say About Mirum PharmaceuticalsNovember 14, 2023 | msn.comMorgan Stanley Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight RecommendationNovember 13, 2023 | markets.businessinsider.comMirum Pharmaceuticals’ Growing Momentum: Livmarli’s Continued Success and Expansion Opportunities in Rare Liver Diseases MarketDecember 4, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 13, 2023 | finance.yahoo.comMirum Pharmaceuticals Presents New Data at The Liver Meeting®November 6, 2023 | markets.businessinsider.comMirum Pharmaceuticals: Strong Q3 Performance and Future Growth Potential Reinforce Buy RatingNovember 6, 2023 | markets.businessinsider.comOptimistic Outlook for Mirum Pharmaceuticals: Strong Financial Performance and Potential Market UnlockingNovember 6, 2023 | finance.yahoo.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comMirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 1, 2023 | benzinga.comEarnings Outlook For Mirum PharmaceuticalsNovember 1, 2023 | msn.comMirum Pharmaceuticals Q3 2023 Earnings PreviewOctober 30, 2023 | finance.yahoo.comMirum Pharmaceuticals to Present New Data at The Liver Meeting®October 27, 2023 | finance.yahoo.comMirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023October 25, 2023 | msn.comCantor starts Mirum at overweight, sees peak sales of over $1BOctober 24, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight RecommendationOctober 19, 2023 | markets.businessinsider.comBuy Rating Maintained for Mirum Pharmaceuticals Despite FDA Delays: An Analysis by Leerink PartnersOctober 18, 2023 | msn.comEvercore ISI Group Reiterates Mirum Pharmaceuticals (MIRM) Outperform RecommendationOctober 18, 2023 | markets.businessinsider.comFDA Extension on Mirum’s Livmarli sNDA Review: Minimal Impact and Potential Approval on the HorizonOctober 18, 2023 | markets.businessinsider.comPositive Outlook for Mirum Pharmaceuticals: Ed Arce’s Buy Rating Justified by LIVMARLI’s Potential and Solid MARCH-PFIC Trial ResultsOctober 17, 2023 | finance.yahoo.comMirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic CholestasisOctober 14, 2023 | seekingalpha.comMirum Pharmaceuticals to sell 7.94M shares for holdersOctober 10, 2023 | msn.comJMP Securities Reiterates Mirum Pharmaceuticals (MIRM) Market Outperform RecommendationSee More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees249Year FoundedN/APrice Target and Rating Average Stock Price Target$54.78 High Stock Price Target$77.00 Low Stock Price Target$37.00 Potential Upside/Downside+72.8%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,660,000.00 Net Margins-113.45% Pretax Margin-112.82% Return on Equity-79.52% Return on Assets-28.17% Debt Debt-to-Equity Ratio1.14 Current Ratio5.20 Quick Ratio4.91 Sales & Book Value Annual Sales$144.73 million Price / Sales10.21 Cash FlowN/A Price / Cash FlowN/A Book Value$3.85 per share Price / Book8.23Miscellaneous Outstanding Shares46,614,000Free Float35,399,000Market Cap$1.48 billion OptionableNot Optionable Beta1.21 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 44)President, CEO & Director Comp: $1.09MMr. Peter Radovich M.B.A. (Age 45)Ph.D., Chief Operating Officer Comp: $732.15kDr. Pamela Vig Ph.D. (Age 52)Head of R&D Comp: $678.2kMs. Lara Longpre MBA (Age 53)MSC, Chief Development Officer Comp: $678.2kMr. Eric H. Bjerkholt M.B.A. (Age 63)Chief Financial Officer Andrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 55)Senior Vice President of Human Resources Dr. Ian Clements Ph.D. (Age 54)Consultant Comp: $649.1kMs. Vinita P. KumarSenior vice President of QualityMore ExecutivesKey CompetitorsPOINT Biopharma GlobalNASDAQ:PNTSupernus PharmaceuticalsNASDAQ:SUPNIronwood PharmaceuticalsNASDAQ:IRWDCatalyst PharmaceuticalsNASDAQ:CPRXMerusNASDAQ:MRUSView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 97,047 shares on 11/24/2023Ownership: 0.031%Polar Capital Holdings PlcBought 250,000 shares on 11/22/2023Ownership: 2.521%Tudor Investment Corp Et AlBought 7,167 shares on 11/16/2023Ownership: 0.041%Legal & General Group PlcBought 1,834 shares on 11/15/2023Ownership: 0.049%AQR Capital Management LLCBought 3,317 shares on 11/15/2023Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions MIRM Stock Analysis - Frequently Asked Questions Should I buy or sell Mirum Pharmaceuticals stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks. What is Mirum Pharmaceuticals' stock price target for 2024? 8 equities research analysts have issued twelve-month target prices for Mirum Pharmaceuticals' shares. Their MIRM share price targets range from $37.00 to $77.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts. How have MIRM shares performed in 2023? Mirum Pharmaceuticals' stock was trading at $19.50 on January 1st, 2023. Since then, MIRM shares have increased by 62.6% and is now trading at $31.70. View the best growth stocks for 2023 here. When is Mirum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our MIRM earnings forecast. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its earnings results on Thursday, November, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.07. The firm earned $47.73 million during the quarter, compared to analyst estimates of $34.31 million. Mirum Pharmaceuticals had a negative trailing twelve-month return on equity of 79.52% and a negative net margin of 113.45%. What ETFs hold Mirum Pharmaceuticals' stock? ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP). What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX). When did Mirum Pharmaceuticals IPO? (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Eventide Asset Management LLC (8.49%), Cadian Capital Management LP (3.08%), Polar Capital Holdings Plc (2.52%), Avidity Partners Management LP (2.45%), Adage Capital Partners GP L.L.C. (1.43%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MIRM) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.